NTT Electronics starts shipping 140 Gbaud High-performance Coherent DSP
6.3.2023 21:00:00 EET | Business Wire | Press release
NTT Electronics, a leading supplier of coherent Digital Signal Processor (DSP) solutions to system and module manufacturers worldwide, today announced start of 140 Gbaud high-performance coherent DSP (ExaSPEED GAIA) shipment to customers. ExaSPEED GAIA achieves world's largest transmission capacity of 1.2 Tbit/s per wavelength by utilizing a programmable baud rate of up to 140 Gbaud powered by a flexible coded modulation scheme and advanced 5nm FinFET CMOS process.
“We are excited to add the ExaSPEED GAIA DSP to our product portfolio which cuts the power consumption per bit to half while doubling the baud rate over earlier product offering,” said Satoshi Shigematsu, NTT Electronics General Manager of Broadband System & Device Business Unit. “We believe this high-performance DSP will help our customers offer highly differentiated optical transmission equipment and systems”, he added.
The programmable baud rate can support very fine granularity that enables ExaSPEED GAIA to adapt to a range of links while maximizing spectral efficiency. These include short-reach data center interconnects (DCI), terrestrial metro links with cascaded ROADMs, and ultra-long-haul sub-sea links. Customers can use a wide range of 400G interfaces in 1.2T (3x400GbE) for DCI, 800G (2x400GbE) for metro and 400G (1x400GbE) for sub-sea applications. This capability helps simplify interfaces and optimize Capital/Operational expenditure. Moreover, ExaSPEED GAIA also offers fine capacity tuning in 50G increments to respond to various customer requirements.
Flexible coded modulation is the newly-developed coding scheme to efficiently implement advanced constellation shaping, forward error correction (FEC), and high-order modulation format with high performance and low power. This enables ExaSPEED GAIA to support thousands of operational modes that cover a multitude of customer's transmission links with high energy efficiency. To enhance the performance, ExaSPEED GAIA employs a number of novel compensation algorithms including nonlinear distortion compensation, adaptive fast state of polarization (SOP) tracking, fast device and transmission characteristics estimation, and ultra-long CD compensation for high-baud rate systems*. The performance of ExaSPEED GAIA can be further optimized by combining it with NTT Electronics’ industry-leading high speed coherent driver module (UHB-CDM).
"We are very impressed with the performance of NTT Electronics’ latest ExaSPEED GAIA DSP," commented Hideki Matsui, Vice Head of Photonics System Business Unit, Fujitsu Limited. “This revolutionary DSP makes our products more competitive in the market and enables us to offer innovative solutions. It opens up a new 'terabit era,' which will be a game changer in our industry,” he added.
“This state-of-the-art DSP, we believe would be key to realize the future information-centric society,” said Akio Goto, General Manager of Photonics Device Development Division, NEC Corporation. He also said, “We are excited to introduce ExaSPEED GAIA in conjunction with CDM in our DWDM products to build diverse, high-throughput and green optical networks.”
* https://group.ntt/en/newsrelease/2022/09/05/220905a.html
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20230306005007/en/
Contact information
NTT Electronics Contact :
Atul Srivastava, CEO & CTO
NTT Electronics America, Inc.
Tel : +1-201-556-1770
Email : pr@nel-america.com
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Cosylab Launches PlanOne™ Treatment Planning System for Particle Therapy8.6.2026 09:00:00 EEST | Press release
Cosylab today announced the commercial launch of PlanOne™, a treatment planning system for particle therapy, bringing physics-accurate, radiobiologically informed planning and a unified clinical workflow into a single environment. PlanOne™ is FDA 510(k) cleared. "PlanOne™ began with listening. Over the years, our work on control systems in radiation oncology has put us in direct, ongoing contact with medical physicists and clinical teams at some of the leading facilities in the world," said Mark Pleško, CEO of Cosylab. "Our partners have been clear on what matters most for particle therapy: physics accuracy they can defend, clinical confidence at the point of plan approval, and a platform built to grow with AI and adaptive workflows. We designed PlanOne™ around those three priorities, and we'll keep developing it together with the clinical community that helped shape it." Physics-accurate, radiobiologically informed planning PlanOne™ is built on a GPU-accelerated Monte Carlo dose engin
BitGo MENA Launches Regulated Electronic Trading, Delivering Full Suite Trading Services to the Region8.6.2026 07:00:00 EEST | Press release
BitGo MENA FZE (“BitGo MENA”), a subsidiary of BitGo Holdings, Inc. (NYSE: BTGO) (“BitGo”), the digital asset infrastructure company, today announced the launch of electronic trading in the Middle East and North African (MENA). With this launch, clients can now access a comprehensive trading solution combining BitGo MENA’s established over-the-counter (OTC) trading offering with institutional-grade electronic execution, all operating under BitGo MENA’s Broker-Dealer license from Dubai’s Virtual Assets Regulatory Authority (VARA). The launch further expands BitGo MENA’s regulated product suite under VARA’s oversight, marking another step in the region’s continued buildout of institutional digital asset infrastructure amid growing demand for integrated execution and custody solutions. “The Middle East and North Africa has quickly become one of the most exciting regions in the world for digital assets, with regulators, institutions, and innovators moving with real purpose,” said Mike Bels
Vertex Presents New Data on ALYFTREK ® at European Cystic Fibrosis Conference5.6.2026 19:00:00 EEST | Press release
Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced data demonstrating the potentially transformative impact of treating cystic fibrosis (CF) with ALYFTREK ® (vanzacaftor/tezacaftor/deutivacaftor) in children ages 2 to 5, as well as data from 96-week interim analyses of two open-label extension studies of ALYFTREK in children 6 to 11 years and people 12 years and older demonstrating the long-term safety and efficacy profile of the medicine. The data, presented at the European Cystic Fibrosis Conference, show children ages 2 to 5 with vanzacaftor/tezacaftor/deutivacaftor-responsive genotypes including those who are homozygous for the F508del mutation (F/F) and those who have F508del/minimal function mutations (F/MF)on ALYFTREK had further improvement in CFTR function from a TRIKAFTA ® baseline as measured by sweat chloride (SwCl), with 65% having achieved SwCl <30 mmol/L after treatment with ALYFTREK. Vertex also presented Phase 3 data of children ages 1 to <2 with TRIKAF
Owkin to Build AI Agents as Part of a Multi-Year K Pro Collaboration with Sanofi5.6.2026 14:00:00 EEST | Press release
Owkin, the agentic AI company pioneering Biological Artificial Superintelligence to transform drug discovery and development, today announced a multi-year collaboration with Sanofi to co-develop next-generation biopharma agents, to be backed by a five-year license for K Pro, Owkin’s AI Scientist. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260605704506/en/ K Pro, Owkin's AI scientist for biology, powered by multimodal patient data for smarter biopharma decision making. Owkin and Sanofi have collaborated since 2021 through a €90 million strategic partnership focused on target identification in oncology and patient subgrouping. The collaboration was later expanded to include drug positioning for Sanofi’s immunology pipeline. This new collaboration represents the next evolution in the partnership. During the five-year collaboration, Owkin will lead the end-to-end development of novel AI-driven biopharma agents purpose-built
DFNS Rebrands as the Core Banking Platform for Digital Assets5.6.2026 13:41:00 EEST | Press release
DFNS today announced a rebrand, marking its evolution from a wallet infrastructure to the first core banking platform for digital assets. The company is introducing a new logo, website, and market position as fintechs and institutions move their products and operations onchain. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260603859127/en/ Banks, fintechs, asset managers, trading firms, payment providers, market infrastructures, and clearing houses have stopped asking how to "add crypto." They're asking how to run financial products, controls, workflows, and client services on blockchain rails, with the reliability expected of core infrastructure. Some are going further still, exploring whether the blockchain can serve as the ledger itself, where an account is an onchain object rather than a row in a database. Where IBANs, virtual accounts, and blockchain wallets converge into one governed financial account. “DFNS was built
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom